본문 바로가기
KERD
논문KCI 등재

Infections and immunity: associations with obesity and related metabolic disorders

Amitabha Ray|Melissa J. L. Bonorden|Rajashree Pandit|Katai J. Nkhata|Anupam Bishayee
대한병리학회|2023.01|Journal of Pathology and Translational Medicine|제57권 제1호|pp. 28-42

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19InfectionsParasitesMetabolic disordersImmune cells
주제분류병리학

초록

About one-fourth of the global population is either overweight or obese, both of which increase the risk of insulin resistance, cardiovascular diseases, and infections. In obesity, both immune cells and adipocytes produce an excess of pro-inflammatory cytokines that may play a significant role in disease progression. In the recent coronavirus disease 2019 (COVID-19) pandemic, important pathological characteristics such as involvement of the renin-angiotensin-aldosterone system, endothelial injury, and pro-inflammatory cytokine release have been shown to be connected with obesity and associated sequelae such as insulin resistance/type 2 diabetes and hypertension. This pathological connection may explain the severity of COVID-19 in patients with metabolic disorders. Many studies have also reported an association between type 2 diabetes and persistent viral infections. Similarly, diabetes favors the growth of various microorganisms including protozoal pathogens as well as opportunistic bacteria and fungi. Furthermore, diabetes is a risk factor for a number of prion-like diseases. There is also an interesting relationship between helminths and type 2 diabetes; helminthiasis may reduce the pro-inflammatory state, but is also associated with type 2 diabetes or even neoplastic processes. Several studies have also documented altered circulating levels of neutrophils, lymphocytes, and monocytes in obesity, which likely modifies vaccine effectiveness. Timely monitoring of inflammatory markers (e.g., C-reactive protein) and energy homeostasis markers (e.g., leptin) could be helpful in preventing many obesity-related diseases.

Abstract

About one-fourth of the global population is either overweight or obese, both of which increase the risk of insulin resistance, cardiovascular diseases, and infections. In obesity, both immune cells and adipocytes produce an excess of pro-inflammatory cytokines that may play a significant role in disease progression. In the recent coronavirus disease 2019 (COVID-19) pandemic, important pathological characteristics such as involvement of the renin-angiotensin-aldosterone system, endothelial injury, and pro-inflammatory cytokine release have been shown to be connected with obesity and associated sequelae such as insulin resistance/type 2 diabetes and hypertension. This pathological connection may explain the severity of COVID-19 in patients with metabolic disorders. Many studies have also reported an association between type 2 diabetes and persistent viral infections. Similarly, diabetes favors the growth of various microorganisms including protozoal pathogens as well as opportunistic bacteria and fungi. Furthermore, diabetes is a risk factor for a number of prion-like diseases. There is also an interesting relationship between helminths and type 2 diabetes; helminthiasis may reduce the pro-inflammatory state, but is also associated with type 2 diabetes or even neoplastic processes. Several studies have also documented altered circulating levels of neutrophils, lymphocytes, and monocytes in obesity, which likely modifies vaccine effectiveness. Timely monitoring of inflammatory markers (e.g., C-reactive protein) and energy homeostasis markers (e.g., leptin) could be helpful in preventing many obesity-related diseases.

참고문헌 (182)

  1. Gammone MA, "COVID-19 and obesity : overlapping of two pandemics", Obes Facts, 14, pp.579~585 (2021)
  2. Sattar N, "Obesity as a risk factor for severe COVID-19 : summary of the best evidence and implications for health care", Curr Obes Rep, 10, pp.282~289 (2021)
  3. Dayaramani C, "Cardiovascular disease complicating COVID-19 in the elderly", Medicina (Kaunas), 57, pp.833~ (2021)
  4. Ghilotti F, "Obesity and risk of infections : results from men and women in the Swedish National March Cohort", Int J Epidemiol, 48, pp.1783~1794 (2019)
  5. Dhurandhar NV, "Interaction of obesity and infections", Obes Rev, 16, pp.1017~1029 (2015)
  6. Frydrych LM, "Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality", J Leukoc Biol, 104, pp.525~534 (2018)
  7. Chakraborty S, "Infections : a possible risk factor for type 2 diabetes", Adv Clin Chem, 80, pp.227~251 (2017)
  8. de Heredia FP, "Obesity, inflammation and the immune system", Proc Nutr Soc, 71, pp.332~338 (2012)
  9. Cinkajzlova A, "Adipose tissue immune cells in obesity, type 2 diabetes mellitus and cardiovascular diseases", J Endocrinol, 252, pp.R1~22 (2021)
  10. Iskander K, "Obesity-related complications : few biochemical phenomena with reference to tumorigenesis", Malays J Pathol, 35, pp.1~15 (2013)
  11. Ray A, "Cancer and comorbidity : the role of leptin in breast cancer and associated pathologies", World J Clin Cases, 6, pp.483~492 (2018)
  12. Taylor EB, "The complex role of adipokines in obesity, inflammation, and autoimmunity", Clin Sci (Lond), 135, pp.731~752 (2021)
  13. Fernandez-Riejos P, "Role of leptin in the activation of immune cells", Mediators Inflamm, 2010, pp.568343~ (2010)
  14. Conus S, "Leptin is an eosinophil survival factor", J Allergy Clin Immunol, 116, pp.1228~1234 (2005)
  15. Ahmetaj-Shala B, "Cardiorenal tissues express SARS-CoV-2 entry genes and basigin (BSG", CD147) increases with age in endothelial cells, 2020, pp.5, 1111~1123
  16. Lubbe L, "ACE2 and ACE : structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV", Clin Sci (Lond), 134, pp.2851~2871 (2020)
  17. Wong MK, "Handbook of hormones" (2016), Elsevier Academic Press
  18. Kuba K, "Multiple functions of angiotensinconverting enzyme 2 and its relevance in cardiovascular diseases", Circ J, 77, pp.301~308 (2013)
  19. Varga Z, "Endotheliitis in COVID-19", Pathologe, 41(Suppl 2), pp.99~102 (2020)
  20. Varga Z, "Endothelial cell infection and endotheliitis in COVID-19", Lancet, 395, pp.1417~1418 (2020)
  21. Al-Benna S, "Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients", Obes Med, 19, pp.100283~ (2020)
  22. Al-Sabah S, "COVID-19 : impact of obesity and diabetes on disease severity", Clin Obes, 10, pp.e12414~ (2020)
  23. Cevik M, "Virology, transmission, and pathogenesis of SARS-CoV-2", BMJ, 371, pp.m3862~ (2020)
  24. Albini A, "ACE-2, is expressed on many different cell types:implications for ACE-inhibitor- and angiotensin II receptor blockerbased cardiovascular therapies", Intern Emerg Med, 15, pp.759~766 (2020)
  25. Halim AA, "Clinical characteristics and outcome of ICU admitted MERS corona virus infected patients", Egypt J Chest Dis Tuberc, 65, pp.81~87 (2016)
  26. Badawi A, "Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis", Int J Infect Dis, 49, pp.129~133 (2016)
  27. Honce R, "Impact of obesity on influenza A virus pathogenesis, immune response, and evolution", Front Immunol, 10, pp.1071~ (2019)
  28. Bhattacharya I, "From influenza virus to novel corona virus (SARS-CoV-2): the contribution of obesity", Front Endocrinol (Lausanne), 11, pp.556962~ (2020)
  29. Ndako JA, "Studies on the serological markers for hepatitis B virus infection among type 2 diabetic patients", J Clin Lab Anal, 35, pp.e23464~ (2021)
  30. Iovanescu VF, "Diabetes mellitus and renal involvement in chronic viral liver disease", J Med Life, 8, pp.483~487 (2015)
  31. Cheng AY, "Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients", Diabetologia, 49, pp.1777~1784 (2006)
  32. Virseda Chamorro I, "Hepatitis C as a risk factor of diabetes mellitus type 2", Rev Clin Esp, 206, pp.167~171 (2006)
  33. Arao M, "Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus", J Gastroenterol, 38, pp.355~360 (2003)
  34. Dworzanski J, "Prevalence of Epstein-Barr virus, human papillomavirus, cytomegalovirus and herpes simplex virus type 1 in patients with diabetes mellitus type 2 in south-eastern Poland", PLoS One, 14, pp.e0222607~ (2019)
  35. Karjala Z, "Association between HSV1 seropositivity and obesity : data from the National Health and Nutritional Examination Survey, 2007-2008", PLoS One, 6, pp.e19092~ (2011)
  36. Fernandez-Real JM, "Burden of infection and fat mass in healthy middle-aged men", Obesity (Silver Spring), 15, pp.245~252 (2007)
  37. Sun YH, "Association of herpes simplex virus type2 infection with dyslipidemia in Chinese", Zhonghua Yi Xue Za Zhi, 83, pp.1774~1777 (2003)
  38. Woelfle T, "Health impact of seven herpesviruses on(pre)diabetes incidence and HbA(1c) : results from the KORA cohort", Diabetologia, 65, pp.1328~1338 (2022)
  39. 유슬기, "Impact of Cytomegalovirus Disease on New-Onset Type 2 Diabetes Mellitus: Population-Based Matched Case-Control Cohort Study", Diabetes and Metabolism Journal, 43(6), pp.815~829 (2019), 대한당뇨병학회[DOI]
  40. Chen S, "Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old : results from the Leiden 85-plus study", Immun Ageing, 9, pp.18~ (2012)
  41. Roberts BW, "Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus", South Med J, 98, pp.686~692 (2005)
  42. Chiu B, "Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery", Circulation, 96, pp.2144~2148 (1997)
  43. Reinholdt K, "Incidence of HPV-related anogenital intraepithelial neoplasia and cancer in men with diabetes compared with the general population", Epidemiology, 32, pp.705~711 (2021)
  44. Sobti A, "Logistic regression prediction model identify type 2 diabetes mellitus as a prognostic factor for human papillomavirus-16 associated head and neck squamous cell carcinoma", PLoS One, 14, pp.e0217000~ (2019)
  45. Slama L, "Risk for incident diabetes is greater in prediabetic men with HIV than without HIV", AIDS, 35, pp.1605~1614 (2021)
  46. Kubiak RW, "Clinic-based diabetes screening at the time of HIV testing and associations with poor clinical outcomes in South Africa : a cohort study", BMC Infect Dis, 21, pp.789~ (2021)
  47. Hema A, "Diabetes mellitus and high blood pressure over risk in HIV-infected people followed at Souro Sanou University Hospital Day Hospital, Bobo-Dioulasso 2018", Rev Epidemiol Sante Publique, 69, pp.72~77 (2021)
  48. Jeremiah K, "Diabetes prevalence by HbA1c and oral glucose tolerance test among HIV-infected and uninfected Tanzanian adults", PLoS One, 15, pp.e0230723~ (2020)
  49. Albashir AA, "The potential impacts of obesity on COVID-19", Clin Med (Lond), 20, pp.e109~e113 (2020)
  50. Singh AK, "Role of corticosteroid in the management of COVID-19 : a systemic review and a Clinician’s perspective", Diabetes Metab Syndr, 14, pp.971~978 (2020)
  51. Hughes S, "Bacterial and fungal coinfection among hospitalized patients with COVID-19 : a retrospective cohort study in a UK secondary-care setting", Clin Microbiol Infect, 26, pp.1395~1399 (2020)
  52. Rawson TM, "Understanding the role of bacterial and fungal infection in COVID-19", Clin Microbiol Infect, 27, pp.9~11 (2021)
  53. Cafardi J, "Opportunistic fungal infection associated with COVID-19", Open Forum Infect Dis, 8, pp.ofab016~ (2021)
  54. Taylor M, "Disseminated histoplasmosis in an immunocompetent patient after COVID-19 pneumonia", Cureus, 13, pp.e17269~ (2021)
  55. Amin A, "Root causes of fungal coinfections in COVID-19 infected patients", Infect Dis Rep, 13, pp.1018~1035 (2021)
  56. Erener S. Diabetes, "infection risk and COVID-19", Mol Metab, 39, pp.101044~ (2020)
  57. Choudhary NK, "Mucormycosis : a deadly black fungus infection among COVID-19 patients in India", Clin Epidemiol Glob Health, 12, pp.100900~ (2021)
  58. Kuchi Bhotla H, "Opportunistic mycoses in COVID-19 patients", survivors : epidemic inside a pandemic, 2021, pp.14, 1720~1726
  59. Speth C, "Complement and fungal pathogens : an update", Mycoses, 51, pp.477~496 (2008)
  60. Soni S, "A systematic review on SARS-CoV-2-associated fungal coinfections", J Med Virol, 94, pp.99~109 (2022)
  61. Prusiner SB, "Novel proteinaceous infectious particles cause scrapie", Science, 216, pp.136~144 (1982)
  62. Linden R, "The biological function of the prion protein : a cell surface scaffold of signaling modules", Front Mol Neurosci, 10, pp.77~ (2017)
  63. Sikorska B, "Human prion diseases : from Kuru to variant Creutzfeldt-Jakob disease", Subcell Biochem, 65, pp.457~496 (2012)
  64. Aguilar-Calvo P, "Prion and prion-like diseases in animals", Virus Res, 207, pp.82~93 (2015)
  65. Duyckaerts C, "The prion-like propagation hypothesis in Alzheimer’s and Parkinson’s disease", Curr Opin Neurol, 32, pp.266~271 (2019)
  66. Iadanza MG, "A new era for understanding amyloid structures and disease", Nat Rev Mol Cell Biol, 19, pp.755~773 (2018)
  67. Lee J, "Prion diseases as transmissible zoonotic diseases", Osong Public Health Res Perspect, 4, pp.57~66 (2013)
  68. Tumminia A, "Type 2 diabetes mellitus and Alzheimer’s disease: role of insulin signalling and therapeutic implications", Int J Mol Sci, 19, pp.3306~ (2018)
  69. Kellett KA, "Prion protein and Alzheimer disease", Prion, 3, pp.190~194 (2009)
  70. Sitammagari KK, "Creutzfeldt Jakob disease" (2022), StatPearls Publishing
  71. Collinge J, "A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea", Philos Trans R Soc Lond B Biol Sci, 363, pp.3725~3739 (2008)
  72. Guo Y, "Creutzfeldt-Jakob disease : alterations of gut microbiota", Front Neurol, 13, pp.832599~ (2022)
  73. Yang D, "Implications of gut microbiota dysbiosis and metabolic changes in prion disease", Neurobiol Dis, 135, pp.104704~ (2020)
  74. Fang P, "The microbiome as a modifier of neurodegenerative disease risk", Cell Host Microbe, 28, pp.201~222 (2020)
  75. Liu S, "Gut microbiota and dysbiosis in Alzheimer’s disease : implications for pathogenesis and treatment", Mol Neurobiol, 57, pp.5026~5043 (2020)
  76. Nishiwaki H, "Meta-analysis of gut dysbiosis in Parkinson’s disease", Mov Disord, 35, pp.1626~1635 (2020)
  77. Gasmi Benahmed A, "Association between the gut and oral microbiome with obesity", Anaerobe, 70, pp.102248~ (2021)
  78. Thomas MS, "Dietary influences on gut microbiota with a focus on metabolic syndrome", Metab Syndr Relat Disord, 20, pp.429~439 (2022)
  79. Gradisteanu Pircalabioru G, "Effects of the lipid profile, type 2 diabetes and medication on the metabolic syndrome-associated gut microbiome", Int J Mol Sci, 23, pp.7509~ (2022)
  80. Bielka W, "The role of the gut microbiota in the pathogenesis of diabetes", Int J Mol Sci, 23, pp.480~ (2022)
  81. Gomez-Gutierrez R, "The prion-like phenomenon in Alzheimer’s disease : evidence of pathology transmission in humans", PLoS Pathog, 16, pp.e1009004~ (2020)
  82. Zhou J, "Alzheimer’s disease and prion protein", Intractable Rare Dis Res, 2, pp.35~44 (2013)
  83. Soto C, "Transmissible proteins : expanding the prion heresy", Cell, 149, pp.968~977 (2012)
  84. Liberski PP, "Kuru, the first human prion disease", Viruses, 11, pp.232~ (2019)
  85. Brandner S, "Prion disease : experimental models and reality", Acta Neuropathol, 133, pp.197~222 (2017)
  86. Manuelidis L, "The kuru infectious agent is a unique geographic isolate distinct from Creutzfeldt-Jakob disease and scrapie agents", Proc Natl Acad Sci U S A, 106, pp.13529~13534 (2009)
  87. Ayers JI, "Robust central nervous system pathology in transgenic mice following peripheral injection of alpha-synuclein fibrils", J Virol, 91, pp.e02095-16~ (2017)
  88. Betemps D, "Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by enhanced ELISA", Acta Neuropathol Commun, 2, pp.29~ (2014)
  89. Boluda S, "Differential induction and spread of tau pathology in young PS19tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains", Acta Neuropathol, 129, pp.221~237 (2015)
  90. Guo JL, "Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice", J Exp Med, 213, pp.2635~2654 (2016)
  91. Lam S, "Transmission of amyloid-beta and tau pathologies is associated with cognitive impairments in a primate", Acta Neuropathol Commun, 9, pp.165~ (2021)
  92. Morales R, "Titration of biologically active amyloid-beta seeds in a transgenic mouse model of Alzheimer’s disease", Sci Rep, 5, pp.9349~ (2015)
  93. Wagner J, "Anle138b : a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease", Acta Neuropathol, 125, pp.795~813 (2013)
  94. Wagner J, "Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies", Acta Neuropathol, 130, pp.619~631 (2015)
  95. Ryan SM, "Harnessing helminth-driven immunoregulation in the search for novel therapeutic modalities", PLoS Pathog, 16, pp.e1008508~ (2020)
  96. Khudhair Z, "and alters the composition of gut microbiota in distinct mouse models of type 2 diabetes", Front Endocrinol(Lausanne), 11, pp.606530~ (2020)
  97. Hays R, "Does Strongyloides stercoralis infection protect against type 2 diabetes in humans? Evidence from Australian Aboriginal adults", Diabetes Res Clin Pract, 107, pp.355~361 (2015)
  98. Rajamanickam A, "Metabolic consequences of concomitant Strongyloides stercoralis infection in patients with type 2 diabetes mellitus", Clin Infect Dis, 69, pp.697~704 (2019)
  99. Rajamanickam A, "Helminth infection modulates systemic pro-inflammatory cytokines and chemokines implicated in type 2 diabetes mellitus pathogenesis", PLoS Negl Trop Dis, 14, pp.e0008101~ (2020)
  100. Muthukumar R, "Effects of Opisthorchis viverrini infection on glucose and lipid profiles in human hosts : a cross-sectional and prospective follow-up study from Thailand", Parasitol Int, 75, pp.102000~ (2020)
  101. Htun NS, "Association between helminth infections and diabetes mellitus in adults from the Lao People’s Democratic Republic : a cross-sectional study", Infect Dis Poverty, 7, pp.105~ (2018)
  102. Moudgil V, "Coprevalence of parasitic infections and diabetes in Sub-Himalayan region of Northern India", Int J Health Sci (Qassim), 13, pp.19~24 (2019)
  103. Ambachew S, "The prevalence of intestinal parasites and their associated factors among diabetes mellitus patients at the University of Gondar Referral Hospital, northwest Ethiopia", J Parasitol Res, 2020, pp.8855965~ (2020)
  104. Almugadam BS, "Association of urogenital and intestinal parasitic infections with type 2 diabetes individuals : a comparative study", BMC Infect Dis, 21, pp.20~ (2021)
  105. Udoh BE, "Asymptomatic falciparum malaria and its effects on type 2 diabetes mellitus patients in Lagos, Nigeria", Saudi J Med Med Sci, 8, pp.32~40 (2020)
  106. Wyss K, "Obesity and diabetes as risk factors for severe Plasmodium falciparum malaria : results from a Swedish nationwide study", Clin Infect Dis, 65, pp.949~958 (2017)
  107. Danquah I, "Type 2 diabetes mellitus and increased risk for malaria infection", Emerg Infect Dis, 16, pp.1601~1604 (2010)
  108. Vizzoni AG, "Ageing with Chagas disease : an overview of an urban Brazilian cohort in Rio de Janeiro", Parasit Vectors, 11, pp.354~ (2018)
  109. dos Santos VM, "Frequency of diabetes mellitus and hyperglycemia in chagasic and non-chagasic women", Rev Soc Bras Med Trop, 32, pp.489~496 (1999)
  110. Soltani S, "The probable association between chronic Toxoplasma gondii infection and type 1 and type 2 diabetes mellitus : a casecontrol study", Interdiscip Perspect Infect Dis, 2021, pp.2508780~ (2021)
  111. Li YX, "Toxoplasma gondii infection in diabetes mellitus patients in China : seroprevalence, risk factors, and case-control studies", Biomed Res Int, 2018, pp.4723739~ (2018)
  112. Reeves GM, "A Positive association between T. gondii seropositivity and obesity", Front Public Health, 1, pp.73~ (2013)
  113. Machado ER, "Host-parasite interactions in individuals with type 1 and 2 diabetes result in higher frequency of Ascaris lumbricoides and Giardia lamblia in type 2diabetic individuals", J Diabetes Res, 2018, pp.4238435~ (2018)
  114. Sisu A, "Intestinal parasite infections in diabetes mellitus patients : a cross-sectional study of the Bolgatanga municipality, Ghana", Sci Afr, 11, pp.e00680~ (2021)
  115. Akinbo FO, "Intestinal parasitic infections among diabetes mellitus patients", Biomark Genom Med, 5, pp.44~47 (2013)
  116. Alemu G, "Intestinal parasitosis and associated factors among diabetic patients attending Arba Minch Hospital, Southern Ethiopia", BMC Res Notes, 11, pp.689~ (2018)
  117. van Tong H, "Parasite infection, carcinogenesis and human malignancy", EBioMedicine, 15, pp.12~23 (2017)
  118. Muehlenbachs A, "Malignant transformation of Hymenolepis nana in a human host", N Engl J Med, 373, pp.1845~1852 (2015)
  119. Tyson GL, "Risk factors for cholangiocarcinoma", Hepatology, 54, pp.173~184 (2011)
  120. Huang MH, "Relation of hepatolithiasis to helminthic infestation", J Gastroenterol Hepatol, 20, pp.141~146 (2005)
  121. Chaidee A, "Co-occurrence of opisthorchiasis and diabetes exacerbates morbidity of the hepatobiliary tract disease", PLoS Negl Trop Dis, 12, pp.e0006611~ (2018)
  122. Thinkhamrop K, "Association of comorbidity between Opisthorchis viverrini infection and diabetes mellitus in the development of cholangiocarcinoma among a high-risk population, northeastern Thailand", PLoS Negl Trop Dis, 15, pp.e0009741~ (2021)
  123. Klion AD, "Contributions of eosinophils to human health and disease", Annu Rev Pathol, 15, pp.179~209 (2020)
  124. Shibuya T, "Eosinophilic response in parasitic diseases", Nihon Rinsho, 51, pp.825~831 (1993)
  125. Linnemann LC, "Limited role of mast cells during infection with the parasitic nematode Litomosoides sigmodontis", PLoS Negl Trop Dis, 14, pp.e0008534~ (2020)
  126. Lu F, "The roles of mast cells in parasitic protozoan infections", Front Immunol, 8, pp.363~ (2017)
  127. Mitre E, "Lack of basophilia in human parasitic infections", Am J Trop Med Hyg, 69, pp.87~91 (2003)
  128. Rosales C, "Neutrophils vs. amoebas : immunity against the protozoan parasite Entamoeba histolytica", J Leukoc Biol, 110, pp.1241~1252 (2021)
  129. Passelli K, "The impact of neutrophil recruitment to the skin on the pathology induced by Leishmania infection", Front Immunol, 12, pp.649348~ (2021)
  130. Aitken EH, "Neutrophils and malaria", Front Immunol, 9, pp.3005~ (2018)
  131. Marzullo P, "Lymphocytes and immunoglobulin patterns across the threshold of severe obesity", Endocrine, 45, pp.392~400 (2014)
  132. Yoshimura A, "Association of peripheral total and differential leukocyte counts with obesity-related complications in young adults", Obes Facts, 8, pp.1~16 (2015)
  133. Erdal E, "Platelet-to-lymphocyte ratio(PLR)and plateletcrit(PCT)in young patients with morbid obesity", Rev Assoc Med Bras (1992), 65, pp.1182~1187 (2019)
  134. Dixon JB, "Obesity and the white blood cell count : changes with sustained weight loss", Obes Surg, 16, pp.251~257 (2006)
  135. Xu X, "Obesity is associated with more activated neutrophils in African American male youth", Int J Obes (Lond), 39, pp.26~32 (2015)
  136. Raghavan V, "Relevance of haematologic parameters in obese women with or without metabolic syndrome", J Clin Diagn Res, 10, pp.EC11~EC16 (2016)
  137. Brotfain E, "Neutrophil functions in morbidly obese subjects", Clin Exp Immunol, 181, pp.156~163 (2015)
  138. Nieman DC, "Influence of obesity on immune function", J Am Diet Assoc, 99, pp.294~299 (1999)
  139. Womack J, "Obesity and immune cell counts in women", Metabolism, 56, pp.998~1004 (2007)
  140. Al-Sufyani AA, "Obesity and immune cells in Saudi females", Innate Immun, 17, pp.439~450 (2011)
  141. Furuncuoglu Y, "How obesity affects the neutrophil", lymphocyte and platelet, Eur Rev Med Pharmacol Sci, pp.2016, 20[DOI]
  142. Zahorec R, "Neutrophil-to-lymphocyte ratio, past, present and future perspectives", Bratisl Lek Listy, 122, pp.474~488 (2021)
  143. Karakaya S, "The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obesity", Turk J Med Sci, 49, pp.245~248 (2019)
  144. Dong Jun Kim, "The Associations of Total and Differential White Blood Cell Counts with Obesity, Hypertension, Dyslipidemia and Glucose Intolerance in a Korean Population", Journal of Korean Medical Science, 23(2), pp.193~198 (2008), 대한의학회
  145. Yu JY, "Relationship between inflammatory markers and visceral obesity in obese and overweight Korean adults : an observational study", Medicine (Baltimore), 98, pp.e14740~ (2019)
  146. Syauqy A, "Association of dietary patterns, anthropometric measurements, and metabolic parameters with C-reactive protein and neutrophil-to-lymphocyte ratio in middle-aged and older adults with metabolic syndrome in Taiwan : a cross-sectional study", Nutr J, 17, pp.106~ (2018)
  147. Bahadir A, "Is the neutrophil-to-lymphocyte ratio indicative of inflammatory state in patients with obesity and metabolic syndrome?", Anatol J Cardiol, 15, pp.816~822 (2015)
  148. Yilmaz H, "Usefulness of the neutrophil-tolymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity", Diabetes Metab Syndr, 9, pp.299~304 (2015)
  149. Thavaraputta S, "Relation of hematologic inflammatory markers and obesity in otherwise healthy participants in the National Health and Nutrition Examination Survey, 2011-2016", Proc(Bayl Univ Med Cent), 34, pp.17~21 (2020)
  150. Ip BC, "Lymphocyte roles in metabolic dysfunction : of men and mice", Trends Endocrinol Metab, 26, pp.91~100 (2015)
  151. Bahr I, "Impaired natural killer cell subset phenotypes in human obesity", Immunol Res, 66, pp.234~244 (2018)
  152. Rodriguez CP, "Peripheral lymphocytes, obesity, and metabolic syndrome in young adults : an immunometabolism study", Metab Syndr Relat Disord, 16, pp.342~349 (2018)
  153. Sato Mito N, "Long term effects of high fat and sucrose diets on obesity and lymphocyte proliferation in mice", J Nutr Health Aging, 13, pp.602~606 (2009)
  154. Breznik JA, "Effects of obesity-associated chronic inflammation on peripheral blood immunophenotype are not mediated by TNF in female C57BL", 6J mice, 2021, pp.5, 370~383
  155. Tenorio TR, "Relation between leukocyte count, adiposity, and cardiorespiratory fitness in pubertal adolescents", Einstein (Sao Paulo), 12, pp.420~424 (2014)
  156. Friedrich K, "Perturbation of the monocyte compartment in human obesity", Front Immunol, 10, pp.1874~ (2019)
  157. Christou KA, "Metabolically healthy obesity is characterized by a proinflammatory phenotype of circulating monocyte subsets", Metab Syndr Relat Disord, 17, pp.259~265 (2019)
  158. Subramanian V, "Obesity, inflammation, and macrophages", Nestle Nutr Workshop Ser Pediatr Program, 63, pp.151~159 (2009)
  159. Bastarrachea RA, "Macrophages, inflammation, adipose tissue, obesity and insulin resistance", Gac Med Mex, 143, pp.505~512 (2007)
  160. Shehata HM, "Sugar or fat? : metabolic requirements for immunity to viral infections", Front Immunol, 8, pp.1311~ (2017)
  161. Wiedermann U, "Primary vaccine failure to routine vaccines : why and what to do?", Hum Vaccin Immunother, 12, pp.239~243 (2016)
  162. Young KM, "Is obesity a risk factor for vaccine non-responsiveness?", PLoS One, 8, pp.e82779~ (2013)
  163. Choi J, "Obesity and C-reactive protein in various populations : a systematic review and meta-analysis", Obes Rev, 14, pp.232~244 (2013)
  164. Wu Y, "C-reactive protein and inflammation : conformational changes affect function", Biol Chem, 396, pp.1181~1197 (2015)
  165. Pepys MB, "C-reactive protein : a critical update", J Clin Invest, 111, pp.1805~1812 (2003)
  166. Sproston NR, "Role of C-reactive protein at sites of inflammation and infection", Front Immunol, 9, pp.754~ (2018)
  167. Viikari LA, "Relationship between leptin and C-reactive protein in young Finnish adults", J Clin Endocrinol Metab, 92, pp.4753~4758 (2007)
  168. Hribal ML, "Role of C reactive protein(CRP)in leptin resistance", Curr Pharm Des, 20, pp.609~615 (2014)
  169. Liu Y, "C-reactive protein inhibits high-molecular-weight adiponectin expression in 3T3-L1 adipocytes via PI3K", Akt pathway, 2016, pp.472, 19~25
  170. Naylor C, "Leptin regulation of immune responses", Trends Mol Med, 22, pp.88~98 (2016)
  171. La Cava A, "Leptin in inflammation and autoimmunity", Cytokine, 98, pp.51~58 (2017)
  172. Dayakar A, "Leptin induces the phagocytosis and protective immune response in Leishmania donovani infected THP-1 cell line and human PBMCs", Exp Parasitol, 160, pp.54~59 (2016)
  173. Baltodano-Calle MJ, "Leptin as a potential prognostic marker of the severity of COVID-19 infection in obese patients", Nutr Metab Cardiovasc Dis, 32, pp.743~744 (2022)
  174. Smilowitz NR, "C-reactive protein and clinical outcomes in patients with COVID-19", Eur Heart J, 42, pp.2270~2279 (2021)
  175. Giner-Galvan V, "C-Reactive protein and serum albumin ratio : a feasible prognostic marker in hospitalized patients with COVID-19", Biomedicines, 10, pp.1393~ (2022)
  176. Tonon F, "Discriminatory value of adiponectin to leptin ratio for COVID-19 pneumonia", Int J Endocrinol, 2022, pp.9908450~ (2022)
  177. van der Voort PHJ, "Leptin levels in SARS-CoV-2 infection related respiratory failure : a cross-sectional study and a pathophysiological framework on the role of fat tissue", Heliyon, 6, pp.e04696~ (2020)
  178. Larsson A, "Plasma leptin is increased in intensive care patients with COVID-19 : an investigation performed in the PronMed-Cohort", Biomedicines, 10, pp.4~ (2021)
  179. Blot M, "Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19?", Int J Obes (Lond), 45, pp.2126~2131 (2021)
  180. Wang J, "Leptin correlates with monocytes activation and severe condition in COVID-19 patients", J Leukoc Biol, 110, pp.9~20 (2021)
  181. Honce R, "A tale of two pandemics : obesity and COVID-19", J Travel Med, 27, pp.taaa097~ (2020)
  182. Brandao SCS, "COVID-19and obesity : the meeting of two pandemics", Arch Endocrinol Metab, 65, pp.3~13 (2021)

관련 논문AI추천

Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions김지은, Lee Jongsoon대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2021 · 제26권 제1호The Role of T Cells in Obesity-Associated Inflammation and Metabolic Disease박찬수, Shastri Nilabh대한면역학회 · Immune Network2022 · 제22권 제1호Is Obesity a Potential Risk factor for Poor Prognosis of COVID-19?COVID-19 Team, Dilek Ernam, Elif Yıldırım, Eylem Tuncay, Ipek Ozmen, Meltem Agca, Nazlı Huma Teke, Nermin Ozer Yılmaz, Reyhan Yıldız, Simge Yavuz, Tülin Sevim, Zuhal Karakurt대한감염학회 · Infection and Chemotherapy2021 · 제53권 제2호Impact of Obesity-Related Inflammation on Cardiac Metabolism and FunctionKirsten M. Jansen, Terje S. Larsen한국지질동맥경화학회 · 지질·동맥경화학회지2021 · 제10권 제1호Role of Innate Immunity in Diabetes and Metabolism: Recent Progress in the Study of Inflammasomes이명식대한면역학회 · Immune Network2011 · 제11권 제2호Obesity, Inflammation and Diet이인석, 조여원, 이한송이대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2013 · 제16권 제3호

이 간행물의 다른 논문 (7건)

A standardized pathology report for gastric cancer: 2nd edition국명철, 곽윤진, 구미진, 이원애, 박영수, 강구현, 신옥란, 강동욱, 김경미, 최윤정, 최영희, 김희성, 김백희, 한송희, 송인혜, 장희경, 김현기, 이성학, 서안나, 진소영, 조미연, 이혜승, 안수민, 김준미, 장미수, 박도윤pp. 1-27Single-cell and spatial sequencing application in pathology최진용, 이석형, 김윤섭pp. 43-51Perspectives on single-nucleus RNA sequencing in different cell types and tissues이혜옥, 조아름, 유승아, 김나영, 강희람pp. 52-59Inflammatory bowel disease–associated intestinal fibrosis박지민, 김정석, 이유진, 이혜원, 배성욱pp. 60-66The proteomic landscape shows oncologic relevance in cystitis glandularis정민선, 김혜윤, 한도현, 김준용, 유한석pp. 67-74
원문 보기